Effective combinatorial immunotherapy for castration-resistant prostate cancer

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

(2017) Tomasz M. Beer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

(2016) Matthew Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

(2016) Olivier De Henau et al.   NATURE

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

(2016) Maria I. Carlo et al.   ONCOLOGIST

Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

(2015) Carlotta Costa et al.   CANCER CELL

TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients

(2015) D. M. S. Hossain et al.   CLINICAL CANCER RESEARCH

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression

(2015) G. Wang et al.   Cancer Discovery

Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy

(2015) Lee B. Rivera et al.   Cell Reports

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

(2014) Eugene D Kwon et al.   LANCET ONCOLOGY

Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer

(2014) Diletta Di Mitri et al.   NATURE

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-cell mass cytometry for analysis of immune system functional states

(2013) Zach B Bjornson et al.   CURRENT OPINION IN IMMUNOLOGY

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

(2013) John C Araujo et al.   LANCET ONCOLOGY

Use of PB-Cre4 Mice for Mosaic Gene Deletion

(2013) Andreas Birbach   PLoS One

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling

(2013) Holly M. Nguyen et al.   PLoS One

Telomerase Reactivation following Telomere Dysfunction Yields Murine Prostate Tumors with Bone Metastases

(2012) Zhihu Ding et al.   CELL

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention

(2012) Shidong Jia et al.   Cancer Discovery

VCAM-1 Promotes Osteolytic Expansion of Indolent Bone Micrometastasis of Breast Cancer by Engaging α4β1-Positive Osteoclast Progenitors

(2011) Xin Lu et al.   CANCER CELL

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

(2011) Brett S. Carver et al.   CANCER CELL

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

(2011) Zhihu Ding et al.   NATURE

Molecular genetics of prostate cancer: new prospects for old challenges

(2010) M. M. Shen et al.   GENES & DEVELOPMENT

Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cellsin vitroand in orthotopic mouse model

(2009) Roberta Vitali et al.   INTERNATIONAL JOURNAL OF CANCER

Immunosuppressive CD14+HLA-DRlow/−monocytes in prostate cancer

(2009) Stanimir Vuk-Pavlović et al.   PROSTATE

Overexpression of Interleukin-1β Induces Gastric Inflammation and Cancer and Mobilizes Myeloid-Derived Suppressor Cells in Mice

(2008) Shuiping Tu et al.   CANCER CELL

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS